STOCK TITAN

Alector Inc - ALEC STOCK NEWS

Welcome to our dedicated news page for Alector (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alector's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alector's position in the market.

Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) will host a conference call on February 27, 2024, to discuss fourth-quarter results and provide a full-year business update. The event will be webcast live on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Alector, Inc. and GSK plc announced the dosing of the first patient in the global Phase 2 clinical trial of AL101/GSK4527226, an investigational human monoclonal antibody for early Alzheimer’s disease. The trial aims to enroll approximately 282 patients and is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of two dose levels of AL101 compared to placebo. AL101 has been shown to be generally well tolerated and increased progranulin levels in healthy volunteers. The primary endpoint of the study is disease progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
clinical trial
-
Rhea-AI Summary
Alector, Inc. and GSK plc announced that the U.S. FDA has granted Breakthrough Therapy Designation to latozinemab, an investigational medicine for the treatment of frontotemporal dementia with a progranulin gene mutation (FTD-GRN). This designation is based on data from the INVOKE-2 Phase 2 clinical trial, and latozinemab is currently being studied in the pivotal INFRONT-3 Phase 3 study. The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious conditions with preliminary clinical evidence indicating substantial improvement over available therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
none
Rhea-AI Summary
Alector, Inc. announced the closing of its underwritten public offering of shares of its common stock, selling 10,869,566 shares and granting the underwriter a 30-day option to purchase up to an additional 1,630,434 shares. The gross proceeds to Alector from the offering are approximately $75 million. Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with and subsequently declared effective by the SEC. This press release does not constitute an offer to sell or a solicitation of an offer to buy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
offering
-
Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million. The offering is expected to close on January 19, 2024. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. The offering is made pursuant to a shelf registration statement on Form S-3 that was previously filed with and subsequently declared effective by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.01%
Tags
offering
-
Rhea-AI Summary
Alector, Inc. announced its intention to offer shares of its common stock in an underwritten public offering, with the underwriter having a 30-day option to purchase additional shares. The offering is being made pursuant to a shelf registration statement previously filed with the SEC. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.01%
Tags
offering
Rhea-AI Summary
Alector, Inc. (ALEC) to host virtual events in December to discuss TREM2 and progranulin (PGRN) programs with leading scientific and clinical experts. The events will cover the potential as a therapeutic target for Alzheimer’s Disease and a pivotal stage program for Frontotemporal Dementia with additional opportunities including Alzheimer’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences
-
Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) to participate in fireside chat at Stifel Healthcare Conference on November 14, 2023. Live webcast and replay available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.3%
Tags
conferences
-
Rhea-AI Summary
Alector, Inc. (ALEC) reports successful enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial and completion of INVOKE-2 Phase 2 trial of AL002 for Alzheimer's disease. $588.9 million in cash provides runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.3%
Tags
earnings
Rhea-AI Summary
Alector achieves target enrollment in Phase 3 clinical trial for latozinemab in frontotemporal dementia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
clinical trial
Alector Inc

Nasdaq:ALEC

ALEC Rankings

ALEC Stock Data

602.34M
66.56M
9.99%
80.15%
5.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
South San Francisco

About ALEC

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.